ArticleLeukemia research2013
Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.
Article in Leukemia research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.The oncologist · 2018Pooled it
- Trial
- The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022Article
- Management of the Older Patient with Myelodysplastic Syndrome.Drugs & aging · 2021Review
- Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options.Cancer management and research · 2021Review
- Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.Blood advances · 2020Article
- Article
- Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.Clinical advances in hematology & oncology : H&O · 2018Review
- Assessing Quality of Care for the Myelodysplastic Syndromes.Current hematologic malignancy reports · 2016Review
- Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.Leukemia research · 2015Article
- Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D.Journal of oncology practice · 2015Article
- Resuscitating a dying marrow: the role of hematopoietic growth factors.Current hematologic malignancy reports · 2014Review
- Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies.Medical care · 2014Article
- Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.Medicare & medicaid research review · 2014Observational
- Article
- Current therapy of myelodysplastic syndromes.Blood reviews · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Erythropoiesis-stimulating agents (ESA) are used commonly to reduce symptomatic anemia in patients with myelodysplastic syndromes (MDS). We assessed population-based patterns of ESA use relative to treatment guidelines using data from the Surveillance, Epidemiology, and End Results (SEER) registries, with linked Medicare claims providing detailed treatment data from 2001 through 2005. The study found widespread use (62%) of ESA in Medicare beneficiaries with MDS. Similar ESA use rates regardless of risk status, low frequency (45%) of serum erythropoietin determination prior to ESA initiation, and high prevalence (60.4%) of short-duration ESA episodes suggest clinically important discrepancies between actual practice and guideline-recommended therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.